Nutrition Research
Volume 29, Issue 10 , Pages 685-695 , October 2009

Polymorphism of genes encoding homocysteine metabolism–related enzymes and risk for cardiovascular disease

Received 3 August 2009 ,Revised 11 September 2009 ,Accepted 23 September 2009.

References 

  1. Meshkin B, Blum K. Folate nutrigenetics: a convergence of dietary folate metabolism, folic acid supplementation, and folate antagonist pharmacogenetics. Drug Metab Lett. 2007;1:55–60
  2. Wilson KM, Lentz SR. Mechanisms of the atherogenic effects of elevated homocysteine in experimental models. Semin Vasc Med. 2005;5:163–171
  3. Jacobsen DW, Catanescu O, Dibello PM, Barbato JC. Molecular targeting homocysteine: a mechanism for vascular pathogenesis. Clin Chem Lab Med. 2005;43:1076–1083
  4. Kuo HK, Sorond FA, Chen JH, Hashmi A, Milberg WP, Lipsitz LA. The role of homocysteine in multisystem age-related problems: a systematic review. J Gerontol A Biol Sci Med Sci. 2005;60:1190–1201
  5. Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, et al. The Hordaland homocysteine study: a community-based study of homocysteine, its determinants, and associations with disease. J Nutr. 2006;136:1731S–1740S
  6. Butz LW, du Vigneaud V. The formation of a homologue of cystine by the decomposition of methionine with sulfuric acid. J Biol Chem. 1932;99:135–142
  7. McCully KS. The biomedical significance of homocysteine. J Sci Exploration. 2001;15:5–20
  8. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis. 1975;22:215–227
  9. Kang SS, Wong PW, Malinow MR. Hyperhomocysteinemia as a risk factor for occlusive vascular disease. Ann Rev Nutr. 1992;12:279–298
  10. Trabetti E. Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk. J Appl Genet. 2008;49(3):267–282
  11. Welch GN, Loscalzo J. Homocysteine and atherothromobosis. N Engl J Med. 1998;338:1042–1050
  12. De Bree A, Verschuren WMM, Kromhout D, Kluijtmans LAJ, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev. 2002;54:599–618
  13. Faeh D, Chiolero A, Paccaud F. Homocysteine as a risk factor for cardiovascular disease: should we (still) worry about it?. Swiss Med Wkly. 2006;136:745–756
  14. Clark R, Collins R, Lewington S, Donald A. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288:2015–2022
  15. Makris M. Hyperhomocysteinemia and thrombosis. Clin Lab Haematol. 1999;22:133–143
  16. Challem J, Dolby V. Homocysteine: the new “cholesterol.” McGraw-Hill Contemporary. 1996;
  17. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003;26:137–146
  18. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476–483
  19. Haidemenos A, Kontis D, Gazi A, Kallai E, Allin M, Lucia B. Plasma homocysteine, folate and B12 in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1289–1296
  20. Pols HAP, Yazdanpanah N, van Meurs JBJ. Homocysteine, the vitamin B complex family and bone. Int Congr Series. 2007;1297:151–157
  21. Jakubowski H. Homocysteine-thiolactone and S-nitroso-homocysteine mediate incorporation of homocysteine into protein in humans. Clin Chem Lab Med. 2003;41:1462–1466
  22. Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr. 2001;30:377S–381S
  23. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 1999;13:2277–2283
  24. Finkelstein JD. The metabolism of homocysteine: pathways and regulation. Eur J Pediatr. 1998;157(Suppl 2):S40–S44
  25. O'Leary VB, Mills JL, Pangilinan F, Kirke PN, Cox C, Conley M, et al. Analysis of methionine synthase reductase polymorphisms for neural tube defects risk association. Mol Genet Metab. 2005;85:220–227
  26. Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr. 2006;136:1741S–1749S
  27. Mudd SH, Finkelstein JD, Refsum H, Ueland PM, Malinow MR, Lentz SR, et al. Homocysteine and its disulfide derivatives: a suggested consensus terminology. Arterioscler Thromb Vasc Biol. 2000;20:1704–1706
  28. Goyette P, Pai A, Milos R, Frosst P, Tran P, Chen Z, et al. Gene structure of human and mouse methylenetetrahydrofolate reductase (MTHFR). Mamm Genome. 1998;9:652–656
  29. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111–113
  30. Bailey LB, Gregory JF. Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr. 1999;129:919–922
  31. Födinger M, Wagner OF, Hörl WH, Sunder-Plassmann G. Recent insights into the molecular genetics of the homocysteine metabolism. Kidney Int Suppl. 2001;59(Suppl 78):S238–S242
  32. Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Redlund M, et al. Geographical and ethnic variation of the 677C-T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide. J Med Genet. 2003;40:619–625
  33. Riancho JA, Valero C, Zarrabeitia MT. MTHFR polymorphism and bone mineral density: meta-analysis of published studies. Calcif Tissue Int. 2006;79:289–293
  34. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol. 2007;165:1–13
  35. Castro R, Rivera I, Jakobs C, Blom HJ, Camilo ME, de Almeida IT. 5,10-Methylenetetrahydrofolate reductase 677C→T and 1298A→C mutations are genetic determinants of elevated homocysteine. Q J Med. 2003;96:297–303
  36. Devlin AM, Clarke R, Birks J, Evans JG, Halsted CH. Interactions among polymorphisms in folate-metabolizing genes and serum total homocysteine concentrations in a healthy elderly population. Am J Clin Nutr. 2006;83:708–713
  37. Hustad S, Midttun Ø, Schneede J, Vollset SE, Grotmol T, Ueland PM. The methylenetetrahydrofolate reductase 677C→T polymorphism as a modulator of a B vitamin network with major effects on homocysteine metabolism. Am J Hum Genet. 2007;80:846–855
  38. Zee RYL, Mora S, Cheng S, Erlich HA, Lindpaintner K, Rifai N, et al. Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C→T polymorphism, nutrient intake, and incident cardiovascular disease in 24 968 initially healthy women. Clin Chem. 2007;53:845–851
  39. Huh HJ, Chi HS, Shim EH, Jang S, Park CJ. Gene–nutrition interactions in coronary artery disease: correlation between the MTHFR C677T polymorphism and folate and homocysteine status in a Korean population. Thromb Res. 2006;117:501–506
  40. Vaughn JD, Bailey LB, Shelnutt KP, von-Castel Dunwoody KM, Maneval DR, Davis SR, et al. Methionine synthase reductase 66AG polymorphism is associated with increased plasma homocysteine concentration when combined with the homozygous methylenetetrahydrofolate reductase 677CT variant. J Nutr. 2004;134:2985–2990
  41. Yates Z, Lucock M. Interaction between common folate polymorphisms and B-vitamin nutritional status modulates homocysteine and risk for a thrombotic event. Mol Genet Metab. 2003;79:201–213
  42. Ilhan N, Kucuksu M, Kaman D, Ilhan N, Ozbay Y. The 677 C/T MTHFR polymorphism is associated with essential hypertension, coronary artery disease, and higher homocysteine levels. Arch Med Res. 2008;39:125–130
  43. Kölling K, Ndrepepa G, Koch W, Braun S, Mehilli J, Schömig A, et al. Methylenetetrahydrofolate reductase gene C677T and A1298C polymorphisms, plasma homocysteine, folate, and vitamin B12 levels and the extent of coronary artery disease. Am J Cardiol. 2004;93:1201–1206
  44. Freitas AI, Mendonça I, Guerra G, Brión M, Reis RP, Carracedo A, et al. Methylenetetrahydrofolate reductase gene, homocysteine and coronary artery disease: the A1298C polymorphism does matter. Inferences from a case study (Madeira, Portugal). Thromb Res. 2008;122:648–656
  45. Gorący I, Cyryłowski L, Kaczmarczyk M, Fabian A, Koziarska D, Gorący J, et al. C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of ischemic stroke in Polish subjects. J Appl Genet. 2009;50:63–67
  46. Wang XL, Duarte N, Cai H, Adachi T, Sim AS, Cranney G, et al. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis. 1999;146:133–140
  47. Laraqui A, Allami A, Carrié A, Raisonnier A, Coiffard A-S, Benkouka F, et al. Relation between plasma homocysteine, gene polymorphisms of homocysteine metabolism–related enzymes, and angiographically proven coronary artery disease. Eur J Intern Med. 2007;18:474–483
  48. Wiemels JL, Smith RN, Taylor GM, Eden OB, Alexanderi FE, Greaves MF. United Kingdom Childhood Cancer Study Investigators. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia. Proc Natl Acad Sci U S A. 2001;98:4004–4009
  49. Van der Put NMJ, Gabreëls F, Stevens EMB, Smeitink JAM, Trijbels FJM, Eskes TKAB, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet. 1998;62:1044–1051
  50. Goyette P, Sumner JS, Milos R, Duncan AMV, Rosenblatt DS, Matthews RG, et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. 1994;7:195–200
  51. Kluijtmans LAJ, Wendel U, Stevens EMB, van den Heuvel LPWJ, Trijbels FJM, Blom HJ. Identification of four novel mutations in severe methylenetetrahydrofolate reductase deficiency. Eur J Hum Genet. 1998;6:257–265
  52. Tonetti C, Burtscher A, Bories D, Tulliez M, Zittoun J. Methylenetetrahydrofolate reductase deficiency in four siblings: a clinical, biochemical, and molecular study of the family. Am J Med Genet. 2000;91:363–367
  53. Watkins D, Ru M, Hwang H-Y, Kim CD, Murray A, Philip NS, et al. Hyperhomocysteinemia due to methionine synthase deficiency, cblG: structure of the MTR gene, genotype diversity, and recognition of a common mutation, P1173L. Am J Hum Genet. 2002;71:143–153
  54. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet. 1996;5:1867–1874
  55. Chen LH, Liu M-L, Hwang H-Y, Chen L-S, Korenberg J, Shane B. Human methionine synthase: cDNA cloning, gene localization, and expression. J Biol Chem. 1997;272:3628–3634
  56. Jacques PF, Bostom AG, Selhub J, Rich S, Ellison RC, Eckfeldt JH, et al. Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI Family Heart Study. Atherosclerosis. 2003;166:49–55
  57. Tsai MY, Bignell M, Schwichtenberg K, Hanson NQ. High prevalence of a mutation in the cystathionine β-synthase gene. Am J Hum Genet. 1996;59:1262–1267
  58. Gulati S, Baker P, Li YN, Fowler B, Kruger W, Brody LC, et al. Defects in human methionine synthase in cblG patients. Hum Mol Genet. 1996;5:1859–1865
  59. Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H, et al. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Molec Genet Metab. 1999;67:317–323
  60. Paine MJI, Scrutton NS, Munro AW, Gutierrez A, Roberts GCK, Wolf CR. Electron transfer partners of cytochrome P450 cytochrome P450: structure, mechanism, and biochemistry. 3rd ed.. New York: Kluwer Academic/Plenum Publishers; 2005;
  61. Kraus JP, Oliveriusová J, Sokolová J, Kraus E, Vlček Č deFranchisR, Maclean KN, et al. The human cystathionine b-synthase (CBS) gene: complete sequence, alternative splicing, and polymorphisms. Genomics. 1998;52:312–324
  62. Orendác M, Zeman J, Stabler SP, Allen RH, Kraus JP, Bodamer O, et al. Homocystinuria due to cystathionine beta-synthase deficiency: novel biochemical findings and treatment efficacy. J Inherit Metab Dis. 2003;26:761–773
  63. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, et al. The natural history of homocystinuria due to cystathionine β-synthase deficiency. Am J Hum Genet. 1985;31:1–31
  64. Kluijtmans LAJ, Boers GHJ, Kraus JP, van den Heuvel LPWJ, Cruysberg JRM, Trijbels FJM, et al. The molecular basis of cystathionine β-synthase deficiency in Dutch patients with homocystinuria: effect of CBS genotype on biochemical and clinical phenotype and on response to treatment. Am J Hum Genet. 1999;65:59–67
  65. Meier M Oliveriusova J, Kraus JP, Burkhard P. Structural insights into mutations of cystathionine β-synthase. Biochim Biophys Acta. 2003;1647:206–213
  66. Kožich V, Kraus F, de Franchis R, Fowler B, Boers GH, Graham I, et al. Hyperhomocysteinemia in premature arterial disease: examination of cystathionine beta-synthase alleles at the molecular level. Hum Mol Genet. 1995;4:623–629
  67. Maclean KN, Gaustadnes M, Oliveriusová J, Janosik M, Kraus E, Kožich V, et al. High homocysteine and thrombosis without connective tissue disorders are associated with a novel class of cystathionine beta-synthase (CBS) mutations. Hum Mutat. 2002;19:641–655
  68. Van Oort FVA, Melse-Boonstra A, Brouwer IA, Clarke R, West CE, Katan MB, et al. Folic acid and reduction of plasma homocysteine concentrations in older adults: a dose-response study. Am J Clin Nutr. 2003;77:1318–1323
  69. Brouwer IA, Dusseldorp M, Thomas CMG, Duran M, Hautvast JGAJ, Eskes TKAB, et al. Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomized trial. Am J Clin Nutr. 1999;69:99–104
  70. Lin P-T, Leeb B-J, Changc H-H, Chenga C-H, Tsaid A-J, Huanga Y-C. Low-dose folic acid supplementation reduces homocysteine concentration in hyperhomocysteinemic coronary artery disease patients. Nutr Res. 2006;26:460–466
  71. Eussen SJ, Groot LC, Joosten LW, Bloo RJ, Clarke R, Ueland PM, et al. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr. 2006;84:361–370
  72. Nguyen P, Grajeda R, Melgar P, Marcinkevage J, Flores R, Martorell R. Weekly may be as efficacious as daily folic acid supplementation in improving folate status and lowering serum homocysteine concentrations in Guatemalan women. J Nutr. 2008;138:1491–1498
  73. Guo H, Lee J-D, Ueda T, Cheng J, Shan J, Wang J. Hyperhomocysteinaemia and folic acid supplementation in patients with high risk of coronary artery disease. Indian J Med Res. 2004;119:33–37
  74. Zoungas S, McGrath BP, Branley P, Kerr PG, Muske C, Wolfe R, et al. Cardiovascular morbidity and mortality in the atherosclerosis and folic acid supplementation trial (ASFAST) in chronic renal failure. J Am Coll Cardiol. 2006;47:1108–1116
  75. Ubbink JB, Vermaak WJH, van der Merwe A, Becker PJ, Delport R, Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr. 1994;124:1927–1933
  76. Durga J, van Boxtel MPJ, Schouten EG, Kok FJ, Jolles J, Katan MB, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet. 2007;369:208–216
  77. Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. JAMA. 2008;300:795–804
  78. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. the NORVIT Trial Investigators Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–1588
  79. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielskon E, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease. JAMA. 2008;299:2027–2036
  80. Ho GY-H, Eikelboom JW, Hankey GJ, Wong Ch-R, Tan S-L, Chan JB-C, et al. Methylenetetrahydrofolate reductase polymorphisms and homocysteine-lowering effect of vitamin therapy in Singaporean stroke patients. Stroke. 2006;37:456–460
  81. Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators . Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567–1577
  82. World Health Organization and Agriculture Organization of the United Nations . Vitamin and mineral requirements in human nutrition. 2nd ed.. 2004;China
  83. Sauer J, Mason JB, Choi S-W. Too much folate: a risk factor for cancer and cardiovascular disease?. Curr Opin in Clin Nutr Metab Care. 2009;12:30–36
  84. Gąsiorowska D, Korzeniowska K, Jabłecka A. Homocysteine. Farm Współ. 2008;1:169–175
  85. Walter JH, Wraith JE, White FJ, Bridge C, Till J. Strategies for the treatment of cystathionine β-synthase deficiency: the experience of the Willink Biochemical Genetics Unit over the past 30 years. Eur J Pediatr. 1998;157(S2):S71–S76
  86. Kang S-S. Treatment of hyperhomocyst(e)inemia: physiological basis. J Nutr. 1996;126:1273S–1275S
  87. Van der Linden IJM, Afman LA, Heil SG, Blom HJ. Genetic variation in genes of folate metabolism and neural-tube defect risk. Proc Nutr Soc. 2006;65:204–215
  88. Czeczot H. Folic acid in physiology and pathology. Postepy Hig Med Dosw. 2008;62:405–419
  89. Ng X, Boyd L, Dufficy L, Naumovski N, Blades B, Travers C, et al. Folate nutritional genetics and risk for hypertension in an elderly population sample. J Nutrigenet Nutrigenomics. 2009;2:1–8

PII: S0271-5317(09)00175-4

doi: 10.1016/j.nutres.2009.09.018

Nutrition Research
Volume 29, Issue 10 , Pages 685-695 , October 2009

Article Tools

* Image Usage & Resolution